“We are extremely pleased with how the ENERGY 3 trial is progressing,” said Douglas A. Treco, Ph.D., CEO and Chairman of Inozyme (INZY) Pharma. “The consistency we have observed across safety, immunogenicity, and increases in phosphate levels reinforces our conviction in INZ-701’s ability to address the underlying biology of ENPP1 Deficiency. With no dropouts or dose modifications to date, the emerging profile in pediatric patients is highly encouraging. As we move toward topline data in the first quarter of 2026, we believe INZ-701 is well positioned to become the first approved therapy for this serious and underserved disease.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- INZY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Promising Potential of INZ-701 in Treating ENPP1 Deficiency Drives Buy Rating for Inozyme Pharma
- Inozyme announces JBMR Plus publication on ENPP1 deficiency
- Buy Rating on Inozyme Pharma: Promising Potential of INZ-701 and Market Opportunity